


5

CLAIMS

What is claimed is:

1. A compound comprising




or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

- 15 A is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ , wherein 1 or 2 carbon atoms may be substituted with S or O;

X is selected from the group consisting of  $CO_2H$ ,  $CONHR_2$ ,  $CONR_2$ ,  $CON(OR)R$ ,  $CON(CH_2CH_2OH)_2$ ,  $CONH(CH_2CH_2OH)$ ,  $CH_2OH$ ,  $P(O)(OH)_2$ ,  $CONHSO_2R$ ,  $SO_2NR_2$ ,  $SO_2NHR$ , and




- 20 J is  $C=O$ ,  $CHOH$ , or  $CH_2CHOH$ ;

R is independently H,  $C_1$ - $C_6$  alkyl, phenyl, or biphenyl; and


E is  $C_3$ - $C_6$  alkyl,  $C_4$ - $C_{10}$  cycloalkyl, phenyl or naphthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms.

- 25 2. The compound of claim 1 comprising



5 or a pharmaceutically acceptable salt or a prodrug thereof.

3. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

4. The compound of claim 3 wherein J is C=O.


10 5. The compound of claim 3 wherein J is CHOH.

6. The compound of claim 3 wherein X is CO<sub>2</sub>H.

7. The compound of claim 3 wherein E is phenyl, thienyl, furyl, pyridinyl, naphthyl, benzothienyl, or benzofuryl having from 0 to 2 substituents comprising up to 4 non-hydrogen atoms.


15 8. The compound of claim 3 wherein E is *n*-butyl.

9. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.


10. The compound of claim 1 comprising



20


or a pharmaceutically acceptable salt or a prodrug thereof.

- 5 11. The compound of claim 1 comprising



or a pharmaceutically acceptable salt or a prodrug thereof.

12. A liquid composition comprising




- 10 or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

A is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ , wherein 1 or 2 carbon atoms may be substituted with S or O;

- 15 X is selected from the group consisting of  $CO_2H$ ,  $CONHR_2$ ,  $CONR_2$ ,  $CON(OR)R$ ,  $CON(CH_2CH_2OH)_2$ ,  $CONH(CH_2CH_2OH)$ ,  $CH_2OH$ ,  $P(O)(OH)_2$ ,  $CONHSO_2R$ ,  $SO_2NR_2$ ,  $SO_2NHR$ , and




J is  $C=O$ ,  $CHOH$ , or  $CH_2CHOH$ ;

- 20 R is independently H,  $C_1$ - $C_6$  alkyl, phenyl, or biphenyl; and  
E is  $C_3$ - $C_6$  alkyl,  $C_4$ - $C_{10}$  cycloalkyl, phenyl or naphthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms;

5 wherein said liquid is formulated for ophthalmic use.

13. A method comprising administering a compound to a mammal, wherein said method is useful for the treatment of glaucoma or ocular hypertension in said mammal, said compound comprising




10 or a pharmaceutically acceptable salt or a prodrug thereof;

wherein a dashed line represents the presence or absence of a double bond or a triple bond;

A is  $-(CH_2)_6-$ , *cis*  $-CH_2CH=CH-(CH_2)_3-$ , or  $-CH_2C\equiv C-(CH_2)_3-$ , wherein 1 or 2 carbon atoms may be substituted with S or O;

15 X is selected from the group consisting of  $CO_2H$ ,  $CONHR_2$ ,  $CONR_2$ ,  $CON(OR)R$ ,  $CON(CH_2CH_2OH)_2$ ,  $CONH(CH_2CH_2OH)$ ,  $CH_2OH$ ,  $P(O)(OH)_2$ ,  $CONHSO_2R$ ,  $SO_2NR_2$ ,  $SO_2NHR$ , and



J is  $C=O$ ,  $CHOH$ , or  $CH_2CHOH$ ;

20 R is independently H,  $C_1-C_6$  alkyl, phenyl, or biphenyl; and

E is  $C_3-C_6$  alkyl,  $C_4-C_{10}$  cycloalkyl, phenyl or naphthyl having from 0 to 2 substituents, or a heteroaromatic moiety having from 0 to 2 substituents, wherein said substituents comprise up to 4 non-hydrogen atoms.